| http://purl.uniprot.org/citations/33750829 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/33750829 | http://www.w3.org/2000/01/rdf-schema#comment | "Pancreatic ductal adenocarcinoma (PDAC) is characterized by marked desmoplasia and drug resistance due, in part, to poor drug delivery to extravascular tumor tissue. Here, we report that carcinoma-associated fibroblasts (CAFs) induce β5 integrin expression in tumor cells in a TGF-β dependent manner, making them an efficient drug delivery target for the tumor-penetrating peptide iRGD. The capacity of iRGD to deliver conjugated and co-injected payloads is markedly suppressed when β5 integrins are knocked out in the tumor cells. Of note, β5 integrin knock-out in tumor cells leads to reduced disease burden and prolonged survival of the mice, demonstrating its contribution to PDAC progression. iRGD significantly potentiates co-injected chemotherapy in KPC mice with high β5 integrin expression and may be a powerful strategy to target an aggressive PDAC subpopulation."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.org/dc/terms/identifier | "doi:10.1038/s41467-021-21858-1"xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Suzuki K."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Teesalu T."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Ruoslahti E."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Miyamura N."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Sugahara K.N."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Hurtado de Mendoza T."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Kotamraju V.R."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "French R.P."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Lowy A.M."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Braun G.B."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Botta G.P."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/author | "Mose E.S."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/date | "2021"xsd:gYear |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/name | "Nat Commun"xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/pages | "1541"xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/title | "Tumor-penetrating therapy for beta5 integrin-rich pancreas cancer."xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://purl.uniprot.org/core/volume | "12"xsd:string |
| http://purl.uniprot.org/citations/33750829 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/33750829 |
| http://purl.uniprot.org/citations/33750829 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/33750829 |
| http://purl.uniprot.org/uniprot/#_B4DYQ7-mappedCitation-33750829 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/33750829 |
| http://purl.uniprot.org/uniprot/#_A5YM53-mappedCitation-33750829 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/33750829 |
| http://purl.uniprot.org/uniprot/#_G5E8F8-mappedCitation-33750829 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/33750829 |